Angiogenesis has proven to be a key factor in the proliferation of tumor cells within the host. Recent studies have revealed that without the formation of new blood vessels, tumors are unable to receive the blood supply they need to grow bigger than 1 to 2 mm in diameter.
Although Batu Biologics is highly focused on the clinical development of ValloVax, a cancer vaccine targeting tumor endothelium, from a corporate perspective we want to ensure that we have the highest possible chance of inducing the most benefit in patients we are treating.
Several years ago, the promise of immunotherapy was just a dream. Today, with the FDA approval of Provenge, the market entry of immunological checkpoint inhibitors, and the highly encouraging results of the CAR-T cell trials, immunotherapy of cancer is undergoing a renaissance.